Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.196
Sell
RSI(14)
37.311
Neutral
STOCH(KDJ)(9,3,3)
23.437
Sell
ATR(14)
0.741
High Vlolatility
CCI(14)
-231.413
Oversold
Williams %R
91.403
Oversold
TRIX(12,20)
-0.126
Sell
StochRSI(14)
0.000
Sell
Search
Innoviva Inc
INVAAdd to Watchlist
21.970USD
-0.890-3.89%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.62BMarket Cap
3.02P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Innoviva Inc
Currency: USD Updated: 2026-05-15Key Insights
Innoviva Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 16 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 35.40.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Innoviva Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Innoviva Inc Highlights
StrengthsRisks
Innoviva, Inc. is a diversified holding company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio consists of respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI) and ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO, ELLIPTA. The Company's products include GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA (eravacycline) approved for the treatment of complicated intra-abdominal infections in adults. The third product, XACDURO (formerly known as sulbactam-durlobactam or SUL-DUR), is approved for the treatment of hospital-acquired and ventilator-associated pneumonias caused by Acinetobacter in adults. The development pipeline includes zoliflodacin, an investigational treatment for uncomplicated gonorrhea is in Phase III clinical trial.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 32.49% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 411.33M.
Undervalued
The company’s latest PE is 3.02, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 80.96M shares, decreasing 5.11% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 4.13K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
35.400
Target Price
+54.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Innoviva Inc is 9.08, ranking 13 out of 155 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 97.99M, representing a year-over-year increase of 10.56%, while its net profit experienced a year-over-year increase of 500.56%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.61
Operational Efficiency
10.00
Growth Potential
10.00
Shareholder Returns
7.82
Innoviva Inc's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Innoviva Inc is 7.66, ranking 52 out of 155 in the Pharmaceuticals industry. Its current P/E ratio is 3.02, which is 1587.07% below the recent high of 50.90 and 862.16% above the recent low of -22.99.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 16/155
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Innoviva Inc is 8.00, ranking 58 out of 155 in the Pharmaceuticals industry. The average price target is 33.00, with a high of 45.00 and a low of 18.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
35.400
Target Price
+54.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
174
Total
6
Median
8
Average
Company name
Ratings
Analysts
Innoviva Inc
INVA
5
Amgen Inc
AMGN
38
Biogen Inc
BIIB
37
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
34
Vertex Pharmaceuticals Inc
VRTX
33
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Innoviva Inc is 6.69, ranking 89 out of 155 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 23.69 and the support level at 21.02, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
22.646
Sell
MA10
22.708
Sell
MA20
23.068
Sell
MA50
22.932
Sell
MA100
21.982
Sell
MA200
20.766
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Innoviva Inc is 10.00, ranking 1 out of 155 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 109.69%, representing a quarter-over-quarter increase of 1.43%. The largest institutional shareholder is James Simons, holding a total of 4.06M shares, representing 5.49% of shares outstanding, with 24.31% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Dimensional Fund Advisors, L.P.
Sarissa Capital Management, L.P.
State Street Investment Management (US)
Arrowstreet Capital, Limited Partnership
American Century Investment Management, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Innoviva Inc is 7.78, ranking 35 out of 155 in the Pharmaceuticals industry. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.37
VaR
+2.49%
240-Day Maximum Drawdown
+23.53%
240-Day Volatility
+33.89%
Return
Best Daily Return
60 days
+3.50%
120 days
+5.07%
5 years
+13.71%
Worst Daily Return
60 days
-3.89%
120 days
-3.89%
5 years
-7.83%
Sharpe Ratio
60 days
-1.15
120 days
+0.40
5 years
+0.45
Risk Assessment
Maximum Drawdown
240 days
+23.53%
3 years
+23.53%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
+0.39
3 years
+1.04
5 years
+0.09
Skewness
240 days
+1.88
3 years
+1.36
5 years
+0.92
Volatility
Realised Volatility
240 days
+33.89%
5 years
--
Standardised True Range
240 days
+2.68%
5 years
+2.11%
Downside Risk-Adjusted Return
120 days
+65.40%
240 days
+65.40%
Maximum Daily Upside Volatility
60 days
+20.18%
Maximum Daily Downside Volatility
60 days
+18.20%
Liquidity
Average Turnover Rate
60 days
+1.13%
120 days
+1.21%
5 years
--
Turnover Deviation
20 days
-17.19%
60 days
-3.56%
120 days
+3.78%
Peer Comparison
Pharmaceuticals
Innoviva Inc
INVA
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
9.11 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Jazz Pharmaceuticals PLC
JAZZ
8.81 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Royalty Pharma PLC
RPRX
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Kiniksa Pharmaceuticals International PLC
KNSA
8.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Neurocrine Biosciences Inc
NBIX
8.52 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
